# A Study to Evaluate the Safety and Efficacy of Prograf/FK778 and Prograf/MMF in de Novo Kidney Transplant Recipients

> **NCT00282230** · PHASE2 · TERMINATED · sponsor: **Astellas Pharma Inc** · enrollment: 150 (—)

## Conditions studied

- Kidney Transplantation

## Interventions

- **DRUG:** FK778

## Key facts

- **NCT ID:** NCT00282230
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-11
- **Primary completion:** —
- **Final completion:** 2005-10
- **Target enrollment:** 150 (—)
- **Last updated:** 2012-06-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00282230

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00282230, "A Study to Evaluate the Safety and Efficacy of Prograf/FK778 and Prograf/MMF in de Novo Kidney Transplant Recipients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00282230. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*